resDetect™ Therapeutic Antibody & Recombinant Proteins CMC Process Residual Quality Control Solutions
Therapeutic antibodies & recombinant proteins are important critical biopharmaceuticals used to treat variety of diseases. However, their complex production processes can generate various impurities, particularly CMC process residues such as host cell DNA and Protein A residues. These residual impurities can impact the pharmacokinetics, pharmacodynamics, and immunogenicity of the drugs, potentially causing adverse reactions and treatment failures. Ensuring the safety, efficacy, and purity of these drugs is essential and strict regulatory requirements mandate the control of residual impurities in antibody and recombinant protein drugs to ensure patient safety and health.
Our brand, resDetect™, offers comprehensive quality control solutions for detecting process residues, supporting your CMC quality control studies for antibody and recombinant protein drugs.
Deep Dive into Our resDetect™ Therapeutic Antibody & Recombinant Proteins CMC Process Residual Quality Control Solutions
Host Cell Nucleic Acid Residual Detection
- CHO Host Cell Nucleic Acid Residual Detection
- Pichia pastoris Nucleic Acid Residual Detection
- E. coli Nucleic Acid Residual Detection
- HEK293 Host Cell Nucleic Acid Residual Detection
CHO Host Cell Nucleic Acid Residual Detection
CHO cells are essential in developing and producing therapeutic antibodies, including monoclonal antibodies, bispecific antibodies (bsAbs), and antibody-drug conjugates (ADCs). Their high expression capability and stability make them crucial in biopharmaceuticals. However, the production processes can leave residual host cell DNA (resDNA), which poses safety risks such as carcinogenicity and infections. Detecting resDNA is crucial for ensuring the safety and efficacyof drugs in Chemistry, Manufacturing, and Controls (CMC) quality control.
Our resDetect™ CHO resDNA Quantitation Kit (qPCR) addresses the quality control requirements for detecting CHO cell resDNA in drug CMC production.
Figure 1. High sensitivity and broad dynamic range using the CHO resDNA Quantitation Kit. (A) Typical analysis results obtained with Standard 1 (300 pg/μL) to 6 (3 fg/μL). (B) The standard curve of the 10-fold dilution series. PCR efficiency should be 90-110%.
Figure 2. Assay specificity. Standard curves generated using 10-fold serial dilution of CHO genomic DNA (included in the kit).
Resources
Video —— Demonstration of CHO Host Cell Residual Detection Kit Operation
Protocol —— CHO resDNA Quantitation Kit (qPCR)
Brochure —— resDetect™ CMC Process Residual Detection Solutions
FAQ
1. Which sample pre-processing kit works best for CHO Host Cell DNA residual detection?
The resDetect™ resDNA Sample Preparation Kit (Magnetic Beads), catalog # OPA-R005, is the ideal choice. Its elution buffer is compatible with the qPCR detection system's buffer, ensuring optimal amplification efficiency and sample recovery. Additionally, OPA-R023 is a pre-packed version of OPA-R005, designed for use with our nucleic acid pre-processing machines, saving valuable time for our customers.
2. Does the sample pre-processing kit work with nucleic acid extraction instruments from other suppliers/companies?
Absolutely! Our sample pre-processing kits are optimized to be compatible with all major nucleic acid extraction instruments on the market. Their performance and recovery rates have been thoroughly tested and validated.
3. Can our kit handle the challenging conditions in CHO antibody purification?
Absolutely! Our kit is robust enough to handle pH matrices ranging from 3-10 and highly concentrated protein samples up to 150 mg/mL. Rigorous in-house testing and real-world customer trials have confirmed its efficacy. No need for complex sample preparation like pH adjustments or dilutions – just plug and play!
4. Can Buffer NT, Proteinase K, and Buffer LA be mixed ahead of time during pre-processing?
Buffer NT and Buffer LA should be kept separate to avoid salt precipitation and a decrease in extraction efficiency. However, Buffer NT can be mixed with Proteinase K in advance to streamline the workflow in the lab!
Affinity Ligand Residual Detection
Affinity chromatography is the standard for antibody drug purification, with Protein A widely used as a key ligand. Detecting residual Protein A is crucial to ensure the high-quality and safety of antibody drugs during process development and production. resDetect™ offers ready-to-use ELISA kits for detecting residues of natural Protein A, recombinant Protein A, MabSelect SuRe, Prism A, and Amsphere A3 fillers. We also provide customized kits for customers using Protein L and Protein G fillers, accommodating a wide range of antibody purification needs.
We also provide residue detection kits for fillers such as Protein L, VH3, and Protein G, accommodating a wide range of antibody purification needs.
Highly Recommended:
resDetect™ Universal Protein A Quick ELISA kit (Boiling-free)
Universality: Detects both natural and structurally conserved recombinant Protein A, as well as common alkali-resistant Protein A mutants like MabSelect SuRe™ and Prism A.
Simple Sample Preparation: Requires no boiling or centrifugation , saving valuable time.
Method Validation: ICH-compliant validation reports available upon request.
High IgG Concentration Tolerance: Provides accurate quantification of antibodies up to 20 mg/mL.
The minimum detectable concentration of different forms of protein A are 40 pg/mL. The minimum detectable concentration was determined by adding twice standard deviations to the mean optical density value of twenty zero standard replicates and calculating the corresponding concentration.
The sample batch samples (6) were tested by ACRO and Competitor C’s Kits. The Protein A final concentration ratio between them is 0.6-3.4.
The same lot (53) samples were tested by those two kits. The acceptable recovery rate of ACRO (RES-A029) was 85%, and competitor C was 21%.
For Bevacizumab and Toripalimab, at low spiked concentration of Protein A (0.01ppm) level, Acro is better than Competitor C; meanwhile at high spiked concentration of Protein A (0.05ppm) level, the recovery rate of both are acceptable. For IVIG, the recovery rate for competitor C is not acceptable at both low and high spiked concentration of Protein A. But the recovery rate performance of ACRO are good at both levels. The results indicated that ACRO (RES-A029) was well tolerated when detecting Protein A residue in 20mg/mL IVIG.
The same batch of sample (8) were tested by ACRO (RES-A929) and competitor P’s kit. The Protein A final concentration ratio between them is 1.1-10.9.
3 samples were purified by Protein G, and no Protein A residue since they were not purified by Protein A. The OD450 signal of 3 samples tested by ACRO(RES-A029) was below the blank+2SD. It means there is no Protein A residue in those samples. But the OD450 signal of the same samples tested by Competitor P was far beyond the blank+2SD. It means there are non-specific binding of Competitor P kit.
For Bevacizumab，the recovery rate for both kits are acceptable at low and high spiked Protein A level.
For Toripalimab, at low spiked concentration of Protein A (0.01ppm) level, Acro is better than Competitor P; meanwhile at high spiked concentration of Protein A (0.05ppm) level, the recovery rate of both are acceptable.
For IVIG, the recovery rate for competitor P is not acceptable at both low and high spiked concentration of Protein A. But the recovery rate performance of ACRO are good at both levels. The results indicated that ACRO (RES-A029) was well tolerated when detecting Protein A residue in 20mg/mL IVIG.
FAQ
1. Which Protein A ligands is resDetect™ Universal Protein A Quick ELISA Kit (RES-A029) suitable for?
This assay kit is suitable for detecting natural or structurally conserved recombinant Protein A, including alkali-resistant recombinant Protein A used in bioprocess manufacturing ,such as MabSelect SuRe™, MaXtar® ARPA ligand (from Bio-Link). For other types of Protein A mutant variants used in affinity chromatography resins for antibody purification, it is recommended to obtain corresponding Protein A mutant standard protein solutions from the resin supplier. These standards should be stored under recommended conditions and diluted according to the assay kit instructions to fall within the concentration range of the standard curve for quantification. If the resin supplier cannot provide the specific Protein A mutant standard protein solutions, you may use the Protein A standard in the kit that is closest in characteristics for standard curve establishment and testing.
2. Why should matched standards be used for Protein A residual detection with purification fillers?
According to USP 1103 requirements for enzyme-linked immunosorbent assay (ELISA) methods: "Quantitative assays determine the quantity of the analyte based on the interpolation of a standard calibration curve with known analyte concentration, run simultaneously in the same assay. This standard should be an appropriate, preferably homologous, reference or calibration material that is representative of the analyte(s) of interest." Regulatory agencies recommend using matched standards to ensure the accuracy and reliability of assay results.
Figure 1. Standard curves plotted with standards from different sources
When comparing absorbance values plotted with Protein A from a generic kit and PrismA standards (see Figure 1), significant differences become evident. This discrepancy illustrates that accuracy in detecting residual ligands released from PrismAis substantially reduced when using generic standards for samples purified with PrismA. Therefore, to achieve more accurate results, it is recommended to use standards that match the purification fillers used in your process for calibrating sample measurements.
3. In Protein A residual detection experiments, how do you ensure the accuracy of spiked sample detection?
For samples containing Protein A residuals, where the residual amount cannot be predicted beforehand, it is recommended to start by diluting the samples at low dilution factors. At each dilution factor, spike the sample with a standard at a midpoint concentration to perform spiked sample detection and calculate the spike recovery rate. Ideally, the spike amount should closely match or equivalent to the analyte's concentration, with spike amount not exceeding three times the analyte's concentration. Post spiking, the measured value should not exceed 90% of the method's upper limit of quantification.
For example, if the Protein A residual value in a sample diluted 2-fold measures at 1.559, nearing the quantification limit, and when spiked with 0.2 ng/mL, the spike amount is notably lower than the residual amount, impacting accuracy in recovery rate. Through increasing the dilution factor, the measured value declines post dilution, nearing the spike amount and thereby ensuring acceptable spike recovery rates.
- Background
- Deep Dive into Our resDetect™ Therapeutic Antibody & Recombinant Proteins CMC Process Residual Quality Control Solutions
- Host Cell Nucleic Acid Residual Detection
- Affinity Ligand Residual Detection